Petvivo Holdings, Inc. to Exhibit at the Western Veterinary Conference in Las Vegas, Nevada
MINNEAPOLIS, Feb. 19, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, OTC:PETVW) ("PetVivo") an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets announced today it will be exhibiting at the Western Veterinary Conference to be held March 2nd to March 5th, 2025 at the Mandalay Bay Convention Center in Las Vegas, Nevada.
PetVivo intends to exhibit its innovative product, SPRYNG® with OsteoCushion® Technology, an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles. The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal's subsynovial tissue. Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.
PetVivo further intends to exhibit its new product, PrecisePRP®, a first-in-class off-the-shelf platelet-rich plasma (PRP) product designed for use by veterinarians. PrecisePRP is a leucoreduced, allogeneic, pooled, freeze-dried PRP intended to provide a species-specific source of concentrated platelets in plasma for intra-articular administration in dogs and horses. Unlike any PRP mechanical kits currently on the market, PrecisePRP™ does not require a blood draw or centrifugation making it a truly off-the-shelf product that is easy and convenient. Perhaps more important is the uniformity and consistency that PrecisePRP® guarantees. Each vial of PrecisePRP® contains a consistent dose of 4 billion platelets per vial at a concentration of 500,000 platelets per microliter and is leucoreduced with less than 1500 white blood cells per microliter.
WVC is the largest veterinary conference that services the western part of the United States, and normally plays host to more than 15,000+ participants including many of the top industry professionals.
"We are incredibly excited to participate in this year's Western Veterinary Conference. The WVC provides us an excellent venue to speak with veterinarians about our two innovative products that may be used for the management of osteoarthritis, Spryng, with OsteoCushion Technology and PrecisePRP" said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. "We are looking forward to the opportunity in meeting with veterinarians at the WVC to explain the benefits of Spryng and PrecisePRP and how it may be used to enhance the lives of equine and companion animals."
For more information about PetVivo Holdings, Inc. please contact info1@petvivo.com or visit https://petvivo.com/ and https://www.sprynghealth.com.
Conference Exhibit Details: Western Veterinary Conference (WVC)
Booth #: 1717
PetVivo Representatives Attending: Bryan Monninger, VP of Distribution and Corporate Accounts, April Boyce, VP of Sales and Marketing, and Dr. Kirsty Husby, Senior Technical Services Veterinarian
Dates:
Monday, March 3, 2025 9:00am – 5:00pm
Tuesday, March 4, 2025 9:00am – 5:00pm
Wednesday, March 5, 2025 9:00am – 2:00pm
Location: Mandalay Bay Convention Center in Las Vegas, Nevada
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCQB:PETV, OTC:PETVW) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twenty-one patents protects the Company's biomaterials, products, production processes and methods of use. The Company's lead product SPRYNG™ with OsteoCushion™ technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses, is currently available for commercial sale.
For more information about PetVivo Holdings, Inc. and our revolutionary product, Spryng with OsteoCushion Technology, please contact [email protected] or visit https://petvivo.com/ or http://www.sprynghealth.com.
CONTACT:
John Lai, CEO
PetVivo Holdings, Inc.
Email: [email protected]
(952) 405-6216
Forward-Looking Statements:
The foregoing material may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company's proposed development and commercial timelines, and can be identified by the use of words such as "may," "will," "expect," "project," "estimate," "anticipate," "plan," "believe," "potential," "should," "continue" or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company's business are described in detail in the Company's Annual Report on Form 10-K for the year ended March 31, 2023 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
